Publications
The impact of PDPs on the price of medication for the Unified Health System
CTS-Ipea researchers present a summary of contributions of academic works whose focus was on evaluating PDPs regarding their objective of protecting the interests of public administration by seeking economic viability and advantages regarding the price of SUS’s strategic products.
First published in 07/18/2023 - Last updated in 07/18/2023 às 9:58 pm
The Productive Development Partnerships (Parcerias para o Desenvolvimento Produtivo – PDPs) aim to expand access to medicines and health products considered strategic for the Unified Health System (Sistema Único de Saúde – SUS) through partnerships between public institutions and private companies.
Through them, the Ministry of Health determines a list of strategic products to be acquired (i.e., medication, vaccines, blood products, and health products), which represent a large cost for the government or a relevant weight in the import basket. The companies are committed to transferring the technology to public laboratories in the country and, in exchange, they can manufacture it with guaranteed sales for a period of up to 10 years. After that time, the public laboratory owns the technology.
Created in 2012, the PDPs formalized provisions foreseen in the 2008 National Program for Fostering Public Production and Innovation in the Industrial Health Complex. They also allowed Brazilian companies to enter the field of so-called biosimilars, medicines that result from biological processes.
In this Technical Note, economists Tulio Chiarini and Larissa de Souza Pereira, researchers at the Center for Research on Science, Technology and Society of the Institute for Applied Economic Research (CTS-Ipea), present a summary of contributions of academic works whose focus was on evaluating PDPs regarding their objective of protecting the interests of public administration by seeking economic viability and advantages regarding the price of SUS’s strategic products.
Through them, the Ministry of Health determines a list of strategic products to be acquired (i.e., medication, vaccines, blood products, and health products), which represent a large cost for the government or a relevant weight in the import basket. The companies are committed to transferring the technology to public laboratories in the country and, in exchange, they can manufacture it with guaranteed sales for a period of up to 10 years. After that time, the public laboratory owns the technology.
Created in 2012, the PDPs formalized provisions foreseen in the 2008 National Program for Fostering Public Production and Innovation in the Industrial Health Complex. They also allowed Brazilian companies to enter the field of so-called biosimilars, medicines that result from biological processes.
In this Technical Note, economists Tulio Chiarini and Larissa de Souza Pereira, researchers at the Center for Research on Science, Technology and Society of the Institute for Applied Economic Research (CTS-Ipea), present a summary of contributions of academic works whose focus was on evaluating PDPs regarding their objective of protecting the interests of public administration by seeking economic viability and advantages regarding the price of SUS’s strategic products.
Click here to access the full text.
